Cisplatin-based chronotherapy for advanced non-small cell lung cancer patients: a randomized controlled study and its pharmacokinetics analysis

AbstractPurpose We intended to evaluate the superiority of cisplatin-based chronotherapy in the treatment of patients with advanced non-small cell lung cancer (NSCLC) and investigate the relationship between the circadian rhythm and the variability of pharmacokinetics for cisplatin.MethodsForty-one patients with advanced NSCLC were divided into two groups with minimization randomization, including routine group (24 cases) and chronotherapy group (17 cases). The clinical effect and toxicity between the two groups were investigated. The population pharmacokinetics of cisplatin was calculated using nonlinear mixed-effects modeling method.ResultsThere is no significant difference in total response rate between chronotherapy group (52.94 %) and routine chemotherapy group (50.00 %), p = 0.853. The rate of leucopenia (grade 3 or 4) in chronotherapy group (11.76 %) is significantly lower than that in routine chemotherapy (37.50 %), p < 0.05. The rate of neutropenia (grade 3 or 4) in chronotherapy group (11.76 %) is significantly lower than that in routine chemotherapy group (33.33 %), p < 0.05. The proportion of gastrointestinal toxicity (nausea, grade 1 vs 2) in chronotherapy group is significantly lower than that in routine chemotherapy, p < 0.05. When cisplatin was administered at 18:00, the CL was 1.38- and 1.22-fold higher than those administered at 6:00 for total and unbound cisplatin, respectively (p < 0.05).ConclusionsCisplatin-based chronotherapy has advantage in relieving side effects of chemotherapy, and circadian could influence the metabolism of cisplatin, and more clinical researches are needed.

[1]  U. Garg,et al.  Cisplatin pharmacokinetics in a child receiving peritoneal dialysis , 2010, Pediatric Nephrology.

[2]  T. Kubota,et al.  Pharmacokinetics of cis‐diamminedichloroplatinum (II) given as low‐dose and high‐dose infusions , 1996, Journal of surgical oncology.

[3]  Steven E Schild,et al.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. , 2008, Mayo Clinic proceedings.

[4]  S. Urien,et al.  Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients , 2004, Cancer Chemotherapy and Pharmacology.

[5]  F. Lokiec,et al.  Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. , 2004, British journal of clinical pharmacology.

[6]  A. Reinberg,et al.  Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Jie Li,et al.  Circadian variability of pharmacokinetics of cisplatin in patients with non-small-cell lung carcinoma: analysis with the NONMEM program , 2013, Cancer Chemotherapy and Pharmacology.

[8]  T. Ciuleanu,et al.  Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients , 2009, Cancer Chemotherapy and Pharmacology.

[9]  Albert Goldbeter,et al.  Identifying mechanisms of chronotolerance and chronoefficacy for the anticancer drugs 5-fluorouracil and oxaliplatin by computational modeling. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[10]  F. Lévi,et al.  Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. , 1994, Journal of the National Cancer Institute.

[11]  Tudor Ciuleanu,et al.  Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. , 2006, Lung cancer.

[12]  G. Giaccone,et al.  Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. , 2010, The Lancet. Oncology.

[13]  Peng Huang,et al.  The Circadian Gene Period2 Plays an Important Role in Tumor Suppression and DNA Damage Response In Vivo , 2002, Cell.

[14]  S. Atagi,et al.  Population pharmacokinetic analysis of cisplatin and its metabolites in cancer patients: possible misinterpretation of covariates for pharmacokinetic parameters calculated from the concentrations of unchanged cisplatin, ultrafiltered platinum and total platinum. , 2001, Japanese journal of clinical oncology.

[15]  Francis Lévi,et al.  Chronotherapeutics: The Relevance of Timing in Cancer Therapy , 2006, Cancer Causes & Control.

[16]  Ueli Schibler,et al.  The circadian PAR-domain basic leucine zipper transcription factors DBP, TEF, and HLF modulate basal and inducible xenobiotic detoxification. , 2006, Cell metabolism.

[17]  J. Verweij,et al.  Population pharmacokinetics of cisplatin in adult cancer patients , 2004, Cancer Chemotherapy and Pharmacology.

[18]  A. Ohtsu,et al.  Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer , 2012, Cancer Chemotherapy and Pharmacology.

[19]  F. Lévi,et al.  Chronotherapy and the molecular clock: Clinical implications in oncology. , 2010, Advanced drug delivery reviews.

[20]  Thomas J. Smith,et al.  2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Albert Goldbeter,et al.  Time-patterned drug administration: insights from a modeling approach , 2002, Chronobiology international.

[22]  Toru Ishibashi,et al.  Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients. , 2003, British journal of clinical pharmacology.

[23]  G. Giaccone,et al.  American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. , 2010, Journal of oncology practice.

[24]  S. Gery,et al.  The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. , 2006, Molecular cell.

[25]  W. Hrushesky.  Circadian timing of cancer chemotherapy. , 1985, Science.

[26]  C. Verschraegen,et al.  A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors , 2009, Cancer Chemotherapy and Pharmacology.